Computational and Mathematical Methods in Medicine

Research Article

[Retracted] Efficacy and Safety of Jinshuibao Capsule in Diabetic Nephropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Table 2

Summary of the randomized controls trials of JSBC for DN.
Study (author/year)Sample sizeDuration of treatmentIntervention group (regimen)Control group (regimen)Main outcomesIntergroup differences
Higgins (2007) [5]60 (30/30)26 weeks(A) JSBC, plus (B)(B) Valsartan24 h/UAlb; 8hUAER; HbA1c; ACR24 h/UAlb: MD-, 140 [-227.65, -52.35]
8hUAER: MD, -32.17 [-48.68, -15.66]
HbA1c: MD, -0.04 [-0.23.0.15]
ACR: MD, -23.60 [-42.42, -4.78]
Dai (2016) [6]90 (45/45)30 weeks(A) JSBC, plus (B)(B) LPT, plus CT24 h/UAlb; UAER; Scr; HbA1c24 h/UAlb: MD, -36.6 [-44.14, -29.06]
UAER: MD, -25.00 [-225.45, -200.55]
Scr: MD, 0.90 [-3.04, 4.84]
HbA1c: MD, 0.30 [0.08, 0.52]
Chen (2013) [7]40 (20/20)8 weeks(A) JSBC, plus (B)(B) LPT, plus CTUAER; Scr; BUN; HbA1cUAER: MD, -12.98 [-35.38 9.42]
Scr: MD, -11.60 [-28.00, 4.80]
BUN: MD, -1.40 [-2.11, -0.69]
HbA1c: MD, 0.00 [-0.37, 0.37]
Yang (2014) [8]40 (20/20)12 weeks(A) JSBC, plus (B)(B) LPT, plus CTUAER; Scr; BUNUAER: MD, -25.19 [-31.24,-19.14]
Scr: MD, -13.40 [16.93, -9.87]
BUN: MD, -46.10 [-51.31, -40.89]
Zhang (2014) [9]82 (49/33)8 weeks(A) JSBC, plus (B)(B) Irbesartan, plus CTScr; BUN; 24 h/UAlbScr: MD, -16.6 [-22.72, -10.48]
BUN: MD, -0.40 [-0.80, 0.00]
24 h/UAlb: MD, -47.20 [-72.82, -21.58]
Ding (2013a) [10]100 (52/48)2 weeks(A) JSBC, plus (B)(B) Irbesartan, plus CTUAER; Scr; BUNUAER: MD, -0.56 [-3.35, 53.73]
Scr: MD, 8.03 [5.55, 10.51]
BUN: MD, -0.46 [-1.90, 0.98]
Li and Yao (2009) [11]70 (35/35)12 weeks(A) JSBC, plus (B)(B) Irbesartan, plus CTScr; BUN; 24 h/UAlbScr: MD, -15.00 [-20.91, -9.09]
BUN: MD, -1.40 [-2.11, 0.69]
24 h/UAlb: MD, -10.00 [-301.90, 281.90]
Yi et al. (2015) [12]40 (20/20)26 weeks(A) JSBC, plus (B)(B) Irbesartan, plus CTUAER; HbA1c; ACRUAER: MD, -24.20 [-40.32,-8.08]
HbA1c: MD, -0.51 [-1.55,0.53]
ACR: MD, -17.60 [=34.84, -0.36]
Shen et al. (2016a) [13]60 (30/30)8 weeks(A) JSBC, plus (B)(B) Candesartan cilexetilUAER; Scr; BUNUAER: MD, -17.93 [-27.56, -8.30]
Scr: MD, -8.81 [-17.22, -0.40]
BUN: MD, -0.17 [-1.04, 0.70]
Wu and Pan (2014a) [14]68 (34/34)8 weeks(A) JSBC, plus (B)(B) Candesartan cilexetilUAER; Scr; BUNUAER: MD, -19.66 [-29.90, -9.42]
Scr: MD, -6.00 [-22.90, 10.90]
BUN: MD, -0.10 [-1.54, 1.34]
Zhang et al. (2010) [15]120 (64/56)12 weeks(A) JSBC, plus (B)(B) Candesartan cilexetil, plus CTUAER; 24 h/UAlb; HbA1cUAER: MD, -14.60 [-38.17, 8.97]
24 h/UAlb: MD, -140.00 [-277.28,-2.72]
HbA1c: MD, 0.13 [-0.05, 0.31]
Huang et al. (2010) [16]64 (32/32)8 weeks(A) JSBC, plus PCI(B) Perindopril, plus CTUAERUAER: MD, -28.47 [-34.17, -22.77]
Shi (2007) [17]72 (37/35)6 weeks(A) JSBC, plus (B)(B) Fosinopril, plus CTUAERUAER: MS, -29.80 [-35.68, -23.92]
Wang (2013) [18]120 (60/60)6 weeks(A) JSBC, plus (B)(B) Fosinopril, plus CTUAERUAER: MD, -28.13 [-32.57, -23.69]
Xiao et al. (2016) [19]80 (40/40)2 weeks(A) JSBC, plus (B)(B) Telmisartan, plus CTScr; BUN; 24 h/UAlb; ACRScr: MD, 1.60 [-2.84, 6.04]
BUN: MD, -0.10 [-0.53, 0.33]
24 h/UAlb: MD, -40.30 [-50.63, -29.97]
ACR: MD, -34.30 [-42.94, -25.66]
Pan and Shang (2010) [20]60 (38/22)13 weeks(A) JSBC, plus (B)(B) Benazepril, plus CTScr; BUN; 24 h/UAlb; ACRScr: MD, -1.80 [-8.67, 5.07]
BUN: MD, 0.00 [-0.85, 0.85]
24 h/UAlb: MD, -100.00 [-119.84, -80.16]
ACR: MD, -8.05 [-10.98, -5.12]
Wei (2013) [21]80 (52/28)8 weeks(A) JSBC, plus (B)(B) Olmesartan medoxomil, plus CT24 h/UAlb; ACR24 h/UAlb: MD, -100.00 [-119.84,-80.16]
ACR:
Yu et al. (2017) [22]106 (32/21)12 weeks(A) JSBC, plus (B)(B) Atorvastatin, valsartan, plus CTUAER; ScrUAER: MD, -14.25 [-18.01, -10.49]
Scr: MD, -14.25 [-18.01, -10.49]
Zhu and Li (2012) [23]100 (50/50)8 weeks(A) JSBC, plus (B)(B) CTScr; BUN; 24 h/UAlbScr: MD, 43.70 [-76.42, -10.98]
BUN: MD, -1.50 [-2.07, -0.93]
24 h/UAlb: MD, -71.90 [-82.51, -61.29]
Gao (2010) [24]50 (25/25)26 weeks(A) JSBC, plus (B)(B) CTUAER; ScrUAER: MD, 5.36 [-23.26, 33.98]
Scr: MD, 5.36 [-23.26, 33.98]
Jia et al. (2013b) [25]60(30/30)13 weeks(A) JSBC, plus (B)(B) CTUAER; Scr; BUNUAER: MD, -3.10 [-9.44, 3.24]
Scr: MD, -3.10 [-9.44, 3.24]
BUN: MD, -0.30 [-1.20, 0.42]
Li (2016b) [26]120 (64/56)4 weeks(A) JSBC, plus (B)(B) CTScr; BUNScr: MD, -4.34 [-8.27, -0.41]
BUN: MD, -0.17 [-1.04, 0.70]
Wu et al. (2014b) [27]60 (30/30)12 weeks(A) JSBC, plus (B)(B) CTUAER; Scr; BUNUAER: MD, -1.60 [-16.03, 12.83]
Scr: MD, -1.60 [-16.03, 12.83]
BUN: MD, 0.10 [-1.36, 1.56]
Zhong and Guo (2006) [28]60 (30/30)8 weeks(A) JSBC, plus (B)(B) CTUAER; HbA1cUAER: MD, -18.70 [-27.58, -9.82]
HbA1c: MD, -0.20 [-0.68, 0.28]
Liu (2009) [29]60 (30/30)12 weeks(A) JSBC, plus CT(B) Yishen Jiangtang mixture, plus CTUAER; HbA1cUAER: MD, 21.06 [11.53, 30.59]
HbA1c: MD, 0.15 [-0.08, 0.38]
Wang et al. (2006) [30]68 (34/34)8 weeks(A) JSBC, plus CT(B) Lotensin, plus CTUAERUAER: MD, 0.74 [-9.18, 10.66]
Wang (2012) [31]54 (27/27)24 weeks(A) JSBC, plus CT(B) Shenling Baizhu powder, plus CT24 h/UAlb; HbA1c24 h/UAlb: MD, 39.49 [-3.40.82.38]
HbA1c: MD, 0.07 [-0.37, 0.51]